Lakefront Biotherapeutics NV (LKFT) — Cash Flow-to-Debt Ratio
Lakefront Biotherapeutics NV (LKFT) has a Cash Flow-to-Debt Ratio of -0.39x as of June 2026, meaning its operating cash flow of $-34.09 Million could theoretically repay 0% of its total liabilities ($87.52 Million) in one year. See Lakefront Biotherapeutics NV leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Lakefront Biotherapeutics NV Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Lakefront Biotherapeutics NV across 4 annual periods. Check LKFT cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Annual Cash Flow-to-Debt Ratio for Lakefront Biotherapeutics NV (2022–2025)
Year-by-year debt coverage analysis for Lakefront Biotherapeutics NV. For the full cash flow conversion analysis, see LKFT cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.51x | $-257.46 Million | $170.65 Million | ▼ -484.0% |
| 2024 | -0.26x | $-320.03 Million | $1.24 Billion | ▲ +0.6% |
| 2023 | -0.26x | $-405.97 Million | $1.56 Billion | ▼ -14.7% |
| 2022 | -0.23x | $-500.54 Million | $2.21 Billion | — |